6qsw
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine.== | |
| - | + | <StructureSection load='6qsw' size='340' side='right'caption='[[6qsw]], [[Resolution|resolution]] 1.64Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6qsw]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6QSW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6QSW FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=JGT:~{N}-(2-bromanyl-4-methyl-naphthalen-1-yl)-4,5-dihydro-1~{H}-imidazol-2-amine'>JGT</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |
| - | [[Category: | + | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Alternative-complement-pathway_C3/C5_convertase Alternative-complement-pathway C3/C5 convertase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.47 3.4.21.47] </span></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6qsw FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6qsw OCA], [http://pdbe.org/6qsw PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6qsw RCSB], [http://www.ebi.ac.uk/pdbsum/6qsw PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6qsw ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/CFAB_HUMAN CFAB_HUMAN]] Defects in CFB are a cause of susceptibility to hemolytic uremic syndrome atypical type 4 (AHUS4) [MIM:[http://omim.org/entry/612924 612924]]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.<ref>PMID:17182750</ref> <ref>PMID:20513133</ref> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/CFAB_HUMAN CFAB_HUMAN]] Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb. Bb, a serine protease, then combines with complement factor 3b to generate the C3 or C5 convertase. It has also been implicated in proliferation and differentiation of preactivated B-lymphocytes, rapid spreading of peripheral blood monocytes, stimulation of lymphocyte blastogenesis and lysis of erythrocytes. Ba inhibits the proliferation of preactivated B-lymphocytes. | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Alternative-complement-pathway C3/C5 convertase]] | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Adams, C M]] | ||
| + | [[Category: Anderson, K]] | ||
| + | [[Category: Argikar, U]] | ||
| + | [[Category: Crowley, M]] | ||
| + | [[Category: Cumin, F]] | ||
| + | [[Category: Eder, J]] | ||
| + | [[Category: Ehara, T]] | ||
| + | [[Category: Erbel, P]] | ||
| + | [[Category: Flohr, S]] | ||
| + | [[Category: Gerhartz, B]] | ||
| + | [[Category: Harrison, R]] | ||
| + | [[Category: Hughes, N]] | ||
| + | [[Category: Jaffee, B]] | ||
| + | [[Category: Karki, R]] | ||
| + | [[Category: Maibaum, J]] | ||
| + | [[Category: Mainolfi, N]] | ||
| + | [[Category: Mogi, M]] | ||
| + | [[Category: Sedrani, R]] | ||
| + | [[Category: Sellner, H]] | ||
| + | [[Category: Sirockin, F]] | ||
| + | [[Category: Smith, T M]] | ||
| + | [[Category: Sweeney, A Mac]] | ||
| + | [[Category: Valeur, E]] | ||
| + | [[Category: Wiesmann, C]] | ||
| + | [[Category: C3 convertase]] | ||
| + | [[Category: Complement]] | ||
| + | [[Category: Hydrolase]] | ||
| + | [[Category: Immune]] | ||
| + | [[Category: Inhibitor]] | ||
Revision as of 06:49, 27 March 2019
Complement factor B protease domain in complex with the reversible inhibitor N-(2-bromo-4-methylnaphthalen-1-yl)-4,5-dihydro-1H-imidazol-2-amine.
| |||||||||||
Categories: Alternative-complement-pathway C3/C5 convertase | Large Structures | Adams, C M | Anderson, K | Argikar, U | Crowley, M | Cumin, F | Eder, J | Ehara, T | Erbel, P | Flohr, S | Gerhartz, B | Harrison, R | Hughes, N | Jaffee, B | Karki, R | Maibaum, J | Mainolfi, N | Mogi, M | Sedrani, R | Sellner, H | Sirockin, F | Smith, T M | Sweeney, A Mac | Valeur, E | Wiesmann, C | C3 convertase | Complement | Hydrolase | Immune | Inhibitor
